Irina Koffler - Info zur Person mit Bilder, News & Links



	Analystin CEO Mizuho Securities USA Analyst TEVA VRX Laut einer Aktienanalyse Mizuho Says Senior FDA

News

(1 - 4 von 26

–alle anzeigen

)

Pharma giant Valeant looking more desperate than ever

nypost.com

Irina Koffler, an analyst with Mizuho Securities USA, fretted that Valeant's business is so bad that it may not have any option other than to ...

Valeant at 80% buy shows how hard skepticism is for Wall Street - The...

www.theglobeandmail.com

It’s not hard to see why so few people covering the biotech company have been bearish

Mizuho Securities USA Announces Senior US Equity Research Appointment...

www.wallstreet-online.de

... the U.S. investment banking subsidiary of Mizuho Financial Group (NYSE: MFG), has appointed Irina Koffler Managing Director and Senior Analyst leading ...

AstraZeneca Potassium Drug Rejected; Rival Relypsa Roars | Investor's...

www.investors.com

The FDA rejected AstraZeneca's ZS-9 for hyperkalemia, raising hopes for Relypsa's slow-launching rival.

Netzwerk-Profile

Interessen

(1 - 3 von 5

–alle anzeigen

)

5 Top Losers In Healthcare Sector (ADMS, PMD, TTOO...) | Markets...

markets.businessinsider.com

Mizuho analyst Irina Koffler has downgraded Adamas to Underperform from Neutral and has cut the price target for the shares to $5 from $11.

Did Synergy CEO Just Telegraph Phase 3 Success For Plecanatide? |...

seekingalpha.com

And just a few days before Davis' note, Cantor Fitzgerald Analyst Irina Koffler issued a similar note on May 12 pointing to the possibility that ...

Mizuho, Valeant 'Liquidation Scenario'

www.businessinsider.com

This is Mizuho's approximation of what would happen to the company's stock if its management were 'ousted' and it had to sell all of its assets in a fire sale.

Bücher

Mizuho Securities analyst Irina Koffler Quotes

www.quotes.net

Explore some of Mizuho Securities analyst Irina Koffler best quotations and sayings on Quotes.net -- such as 'Valeant( may need) to pay in excess of the

Artikel & Meinungen

(1 - 2 von 5

–alle anzeigen

)

Mallinckrodt price target lowered to $22 from $25 at Mizuho | Awesome...

awesomecapital.wordpress.com

Mizuho analyst Irina Koffler lowered her price target for Mallinckrodt to $22 from $25 citing higher litigation risk, reduced Acthar estimates, and failure of...

Billion Dollar Hedge Fund Iridian Asset Management Loves These Five...

www.insidermonkey.com

David Cohen and Harold Levy, a duo of special situation investors with a focus on depressed stocks that go through significant changes, founded Iridian Asset...

Sonstiges

(1 - 20 von 49

–alle anzeigen

)

IRINA KOFFLER & LARRY KOFFLER's Baby Registry on The Bump

registry.thebump.com

IRINA KOFFLER & LARRY KOFFLER from registered at for their baby shower registry with a due date of . Browse their baby registries.

Paukenschlag: Mylan sticht Teva aus – Aktie im Sinkflug

de.finance.yahoo.com

Oct 04, · Irina Koffler, Analystin bei Mizuho Securities, glaubt nun an eine Kursrallye bei der Mylan-Aktie, das Kursziel auf Sicht von 12 Monaten beträgt 37 Dollar. Bilder anzeigen. Teva meiden, Mylan auf die Watchlist. Mylan könnte einer der großen Profiteure der FDA-Neuregelung sein. Mit dem heutigen Kurssprung schließt die Aktie die Bodenbildung ...

Irina Koffler's following on SoundCloud - Listen to music

soundcloud.com

Listen to Irina Koffler | SoundCloud is an audio platform that lets you listen to what you love and share the sounds you create.. 2 Followers. Stream Tracks...

Bullish Mizuho Says Bausch Health's Long-Term Guidance 'Within ...

finance.yahoo.com

Mizuho's Irina Koffler maintained a Buy rating on Bausch Health Companies while raising the price target from $39 to $41. The Thesis.

Stream Irina Koffler music | Listen to songs, albums, playlists for...

soundcloud.com

Play Irina Koffler and discover followers on SoundCloud | Stream tracks, albums, playlists on desktop and mobile.

EpiPen rival will return to market next year [Video] - Yahoo

www.yahoo.com

Irina Koffler, Mizuho Securities, discusses why she has a buy rating on Mylan even as the news that the company's EpiPen will face more ...

StreetInsider.com

www.streetinsider.com

Ratings by Mizuho Securities (Irina Koffler). More Stocks Rated by Mizuho Securities. Date, Company, Symbol, Type, Rating (Past), PT (Past), Start $

Valeant annual report reveals new issues, company overhauls board

finance.yahoo.com

... catalyst since the business is quite weak and faces a number of headwinds," Mizuho Securities analyst Irina Koffler said in a research note.

Expert - Irina Rivkind Koffler

www.thelifesciencesreport.com

Streetwise Expert Page

More info from Irina Koffler (hope link works) | RLYP Message Board...

www.investorvillage.com

Relypsa, Inc. Message board - Online Community of active, educated investors researching and discussing Relypsa, Inc. Stocks.

Irina Koffler raised her projected price to $30 from $24! Still time...

www.investorvillage.com

Horizon Pharma, Inc. Message board - Online Community of active, educated investors researching and discussing Horizon Pharma, Inc. Stocks.

Allergan's Vraylar Wins FDA Approval for Bipolar Depression

www.insider.com

... in sales of $683 million in and rake in sales of about $1.36 billion by with the label expansion, Mizuho analyst Irina Koffler said.

Corea di Huntington, FDA: nuovi test clinici per farmaco Teva – Daily...

www.dailyhealthindustry.it

Secondo Irina Koffler, AD di Mizuho Securities, “la debolezza di Teva associata a questo evento svanirà a settembre quando l'azienda ...

Attention deficit disorder focus turns to side effects | Evaluate

www.evaluate.com

Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.

Bausch Has a Good Model in Novartis’ Spinoff of Alcon, Analysts Say |...

www.barrons.com

The spinoff provides a valuable framework to value Bausch Health’s Bausch+Lomb, one which shows the inherent upside to a separation of the businesses, Mizuho...

News Analysis: Inversion Premiums Deconstructed

www.itpf.org

News Analysis: Inversion Premiums Deconstructed:

Endo International Jumps on Patent Approval, Still Has Work to Do -...

realmoney.thestreet.com

ENDP shares surge on rare good news but asset sales may still be necessary....ENDP

Jazz Pharma’s sleep disorder treatment gets FDA nod | Physician's...

www.physiciansweekly.com

... and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency's ...

Novel Acne Drug to Be Abandoned (Reuters) | Medpage Today

www.medpagetoday.com

Fails two pivotal trials

Teva Earnings, Zoetis Earnings Beat Estimates; But Teva Stock Slips...

www.investors.com

Teva earnings and Zoetis earnings beat analyst estimates Thursday. But Teva stock slipped on lagging sales. Zoetis sales were in line and Zoetis stock rose.

Verwandte Suchanfragen zu Irina Koffler

Person "Koffler" (1)
Vorname "Irina" (10783)
Name "Koffler" (146)

sortiert nach Relevanz / Datum

Erweiterte Suche

Dossier exportieren

Person-Suchen: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Irina Koffler Person-Info

News

Pharma giant Valeant looking more desperate than ever

Valeant at 80% buy shows how hard skepticism is for Wall Street - The...

Mizuho Securities USA Announces Senior US Equity Research Appointment...

AstraZeneca Potassium Drug Rejected; Rival Relypsa Roars | Investor's...

Netzwerk-Profile

: Irina Koffler aus Mühlacker

pinterest.com: Irina Koffler

Interessen

5 Top Losers In Healthcare Sector (ADMS, PMD, TTOO...) | Markets...

Did Synergy CEO Just Telegraph Phase 3 Success For Plecanatide? |...

Mizuho, Valeant 'Liquidation Scenario'

Bücher

Mizuho Securities analyst Irina Koffler Quotes

Artikel & Meinungen

Mallinckrodt price target lowered to $22 from $25 at Mizuho | Awesome...

Billion Dollar Hedge Fund Iridian Asset Management Loves These Five...

Sonstiges

IRINA KOFFLER & LARRY KOFFLER's Baby Registry on The Bump

Paukenschlag: Mylan sticht Teva aus – Aktie im Sinkflug

Irina Koffler's following on SoundCloud - Listen to music

Bullish Mizuho Says Bausch Health's Long-Term Guidance 'Within ...

Stream Irina Koffler music | Listen to songs, albums, playlists for...

EpiPen rival will return to market next year [Video] - Yahoo

StreetInsider.com

Valeant annual report reveals new issues, company overhauls board

Expert - Irina Rivkind Koffler

More info from Irina Koffler (hope link works) | RLYP Message Board...

Irina Koffler raised her projected price to $30 from $24! Still time...

Allergan's Vraylar Wins FDA Approval for Bipolar Depression

Corea di Huntington, FDA: nuovi test clinici per farmaco Teva – Daily...

Attention deficit disorder focus turns to side effects | Evaluate

Bausch Has a Good Model in Novartis’ Spinoff of Alcon, Analysts Say |...

News Analysis: Inversion Premiums Deconstructed

Endo International Jumps on Patent Approval, Still Has Work to Do -...

Jazz Pharma’s sleep disorder treatment gets FDA nod | Physician's...

Novel Acne Drug to Be Abandoned (Reuters) | Medpage Today

Teva Earnings, Zoetis Earnings Beat Estimates; But Teva Stock Slips...